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In this study, we investigated the use of metabolic oligosaccharide engineering and bio-orthogonal ligation reactions
combined with lectin microarray and mass spectrometry to analyze sialoglycoproteins in the SW1990 human
pancreatic cancer line. Specifically, cells were treated with the azido N-acetylmannosamine analog, 1,3,4-Bu3ManNAz,
to label sialoglycoproteins with azide-modified sialic acids. The metabolically labeled sialoglyproteins were then
biotinylated via the Staudinger ligation, and sialoglycopeptides containing azido-sialic acid glycans were immobilized
to a solid support. The peptides linked to metabolically labeled sialylated glycans were then released from
sialoglycopeptides and analyzed by mass spectrometry; in parallel, the glycans from azido-sialoglycoproteins
were characterized by lectin microarrays. This method identified 75 unique N-glycosite-containing peptides
from 55 different metabolically labeled sialoglycoproteins of which 42 were previously linked to cancer in the
literature. A comparison of two of these glycoproteins, LAMP1 and ORP150, in histological tumor samples
showed overexpression of these proteins in the cancerous tissue demonstrating that our approach constitutes
a viable strategy to identify and discover sialoglycoproteins associated with cancer, which can serve as biomarkers
for cancer diagnosis or targets for therapy.
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Altered patterns of glycosylation are a universal feature
of cancer with sialic acids – which are a group of un-
usual amino-modified acidic sugars ubiquitously dis-
played on the outer ends of mammalian glycan chains
[1] – playing an especially prominent role as tumor-
associated carbohydrate antigens (TACAs) [2,3]. TACAs,
in general, are involved in many biological and patho-
logical processes, such as regulating cellular and molecu-
lar interactions by either masking recognition sites or
serving as recognition determinants [4]. More specific-
ally, altered sialylation of tumor cell surfaces is associ-
ated with several critical malignant properties that
include invasiveness and metastatic potential [5-7]. Cell
surface sialylation is controlled by several factors, which* Correspondence: hzhang32@jhmi.edu
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unless otherwise stated.include regulation of metabolic flux of ManNAc into the
sialic biosynthetic pathway [8,9], changes in the expres-
sion and enzymatic activities of sialyltransferases and
sialidases, and the availability of candidate penultimate
glycan termini on glycoproteins that serve as acceptor
sites for sialylation [5,10].
An interesting observation made about two decades ago
was that cancer cells expressed the non-human “Neu5Gc”
form of sialic acid at much higher levels than normal tis-
sue [11]. The accumulation of Neu5Gc in tumors was at-
tributed to scavenge of dietary Neu5Gc [12], which was
ultimately biosynthetically incorporated into sialylated
TACAs at much higher levels than into the sialoglycans of
healthy cells. Building on the observation, the enhanced
ability of tumors to over-express types of exogenously-
supplied sialic acid other than the canonical human
“Neu5Ac” form, has been proposed as a new approach
to cancer therapy with Neu5Prop and Neu5Phenyl an-
alogs being evaluated for immunotherapy purposesis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tional groups such as the ketone [14] or azide [15] not
normally found in mammalian sugars have been applied
to the preferential delivery of diagnostic or therapeutic
agents to tumors. The emerging success of these strategies
is evident in the recent in vivo demonstration that azido-
modified sialic acids derived from corresponding ManNAc
metabolic precursors are highly expressed in tumors com-
pared to healthy tissues [16].
While a variety of high-throughput approaches have
been used to study sialylated glycoproteins [17], which
include lectin affinity [6,10,18], titanium dioxide affinity
chromatography [19], strong cation exchange columns
[20], conditional hydrazide chemistry [7,18,21-24], or the
combination of diagonal chromatographic technology and
neuraminidase treatments [25], the above-mentioned
metabolic oligosaccharide engineering strategy is an emer-
ging chemical method to analyze glycoproteins that has
become increasingly used in the past decade [15,26]. In
this approach, an unnatural monosaccharide with a bio-
orthogonal functional group can be introduced into the
biosynthetic pathways of living cells and incorporated
into cellular glycoproteins. The bio-orthogonal functional
group can function as a chemical handle and be tagged
with complementary reactive partners via covalent ligation
reactions. An important feature of metabolic oligosacchar-
ide engineering is that the labeling of glycans can occur
in both living cells and animals and the method can
be used to manipulate and study glycosylation events
[27]. Accordingly, this method is becoming valuable for
glycoproteomics studies in both eukaryotic and bacterial
systems with investigation of cancer a particularly active
area of research [27-32].
Based on the selective in vivo incorporation of exogen-
ously supplied monosaccharides into tumors, as discussed
above, we reasoned that a metabolic oligosaccharide en-
gineering approach could be used to meet a present need
in understanding cancer, which is to more thoroughly
characterize the role of sialoglycoproteins in tumor pro-
gression. As a caveat, the selective incorporation of non-
natural sialic acids into tumors could simply be a conse-
quence of the increased metabolic activity of cancer cells
compared to most normal cells found in the body. How-
ever, a previous study where we treated the human
SW1990 pancreatic cancer cell line with the “high flux”
1,3,4-O-Bu3ManNAc analog that increases levels of nat-
ural sialic acid , showed that increased sialylation did not
occur evenly across all glycoproteins. Instead, certain gly-
coproteins did not experience a measurable increase in
sialylation while important cancer-related markers includ-
ing CD44 and integrin α6 [9] as well as EGFR [33] experi-
enced increased levels of sialic acid of 2-fold or more.
Increased levels of natural sialic acid, however, hold less
potential to manipulate or study the system compared toa similar approach where non-natural sialosides are
metabolically installed into cancer-associated glycans.
Therefore, in the present study, we investigated whether
treatment of SW1990 cells with the non-natural azido-
modified sialic acid precursor 1,3,4-O-Bu3ManNAz [34]
would similarly preferentially label cancer-associated
sialoglycans and, by doing so, provide a method for the
discovery, isolation, and study of this important class of
tumor-promoting molecules.
To experimentally verify the incorporation of azido-sialic
acids into cancer-associated glycans, we treated SW1990
cells with 1,3,4-O-Bu3ManNAz and adapted methods
previously used in our groups (as outlined in Figure 1)
to extract and enrich azido-labeled glycopeptides and gly-
coproteins based on the modified Staudinger reaction first
reported by the Bertozzi group [15]. Once enriched, the
samples were analyzed by mass spectrometry to determine
the identity of proteins labeled by azido-modified glycans
and by lectin analysis to gain a sense of the composition
of the actual glycan structures. Once this knowledge was
in hand, we analyzed clinical samples to verify that pro-
teins that were identified were selectively associated with
cancer compared to healthy tissue.
Results
Incorporation of azido-groups into cellular
glycoconjugates
Metabolic oligosaccharide engineering-based incorpor-
ation of 1,3,4-O-Bu3ManNAz into the glycoconjugates of
various cell lines including SW1990 was recently investi-
gated [34], suggesting that 50 μM of analog was an ad-
equate concentration to robustly label sialoglycans without
inducing any noticeable cytotoxicity, growth inhibition, or
other “off-target” effects. The series of experiments shown
in Figure 2 confirmed that 50 μM was an appropriate ana-
log concentration to conduct the metabolic labeling re-
ported in the current study. In particular, SW1990 cells
were treated with 50 μM 1,3,4-O-Bu3ManNAz and then
labeled by adding Click-iT reaction cocktail to conjugate
fluorescent dyes to the azide groups of sialic acids. Fluor-
escent microscopy showed strong azide-derived signal in
1,3,4-O-Bu3ManNAz treated cells and virtually no back-
ground signal in the untreated controls (Figure 2A). In
complementary experiments designed to verify the meta-
bolic incorporation of azido analogs into the glycoconju-
gates of SW1990 cells, proteins were extracted from
treated or untreated cell lysates, biotinylated via a modifi-
cation of the Staudinger ligation reaction [15], separated
by electrophoresis, and evaluated using HRP-streptavidin
(Figure 2B). The data showed the detection of numer-
ous biotinylated proteins of a broad ranges of molecular
weights in lysates derived from 1,3,4-O-Bu3ManNAz
treated cells but virtually no signal from lysates labeled























Figure 1 Strategy for analyzing azide-modified sialoglycoproteins. The strategy used to analyze the samples includes multiple steps as follows:
1) Cells were metabolically labeled using 1,3,4-O-Bu3ManNAz. 2) Proteins were extracted using RIPA buffer at which point samples were divided
with one set of aliquots used for steps 4 and 5 and another set of aliquots used for steps 6 through 9. 3) Azide-labeled proteins were biotinylated
using through the Staudinger reaction using biotin-PEG3-phosphine and excess reagent was removed by protein precipitation. 4) Biotinlabeled,
azide-modified proteins were purified using monomeric avidin agarose. 5) Glycan profiles of biotin-labeled, azide-modified proteins were
determined by lectin microarray analysis. 6) Proteins were trypsin digested after biotinylation. 7) Biotin-labeled peptides were coupled to
streptavidin agarose. 8) PNGase F was used to release the formerly N-glycosylated peptide from the agarose beads. 9) The released peptides
were analyzed by LC-MS.
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lar amounts of proteins were loaded for each blot, con-
firming that the biotin tag was specifically added only to
azido-sugars present in the glycans of analog treated cells
via the intended bioorthogonal ligation reaction between
the azide and phosphine groups.
Lectin microarray analysis
To investigate the glycosylation patterns on azido-sialic
acid containing glycoproteins in pancreatic cancer cells,
our previously developed lectin microarray [35] wasused to bind biotinylated glycoproteins (Figure 1, Steps 4
and 5) that had first been affinity purified by mono-
meric avidin agarose resin from 1,3,4-O-Bu3ManNAz-treated
and control cells (Figure 1, Steps 1–3). Streptavidin-
conjugated Dylight 549 was used to detect the bio-
tinylated azido-sialoglycoproteins on lectin microarray.
No detectable binding signal above background was
obtained from samples from the control cells without
ManNAz analog treatment (Figure 3). In contrast, glyco-
proteins obtained from treated cells showed high bind-
ing intensity to 10 of the 38 lectins on the array with
(A)
M C   T
(B) (C)
C  T
Figure 2 Assessment of metabolic incorporation of azido-modified sialic acids into cellular glycans. (A) Cell surface labeling of SW1990 cells
incubated with 1,3,4-O-Bu3ManNAz for two days. Labeling of the resulting surface azido-glycoconjugates, indicated by green fluorescence, was
achieved by click chemistry with an Alexa488 fluorophore and the cells were counterstained with DAPI (blue fluorescence) as a nucleus marker.
(B) Proteins were harvested from untreated control (denoted by “C”) and treated (denoted by “T”) SW1990 cells and the specific biotinylation of
azide-modified proteins was assessed by Western blots (“M” denotes molecular weight markers). (C) Silver staining of PAGE-separated proteins
from control (denoted “C”) or treated (denoted “T”) SW1990 cells verified that similar amounts of protein were analyzed in both cases.
Figure 3 Glycan analysis of azido-modified glycoproteins. Glycan profiles of azido-modified glycoproteins analyzed by lectin microarray. Fourteen
lectins showed significant binding to treated cells compared to control cells (*p < 0.05 and **p < 0.01). The lectin binding signals were inhibited
by the appropriate mono- and disaccharides.
Tian et al. Clinical Proteomics  (2015) 12:11 Page 4 of 13
Tian et al. Clinical Proteomics  (2015) 12:11 Page 5 of 13a significant difference of p < 0.01 above the background
while binding to four additional lectins showed lower
intensity that was nonetheless significantly above back-
ground levels (p < 0.05). Binding to the lectins was specif-
ically inhibited by a monosaccharide or a disaccharide that
competes the binding to the same lectin, which confirmed
the binding signal was specific (Figure 3). Lectins with sig-
nificant binding signal were DSA, PHA-E, PSA, WFA,
Jacalin, MPA, ECA, UDA, GNA, HHL, NPA, Calsepa,
MNA-G, and VVA (Figure 3 and Table 1). Based on the
glycan-binding specificity of these lectins, among the
N-type glycans, the azide-labeled sialoglycoproteins
contained α-1-6 core fucoses (PSA), Galβ1-4GlcNAc
structures (DSA and PHAE), and high mannose (NPA,
GNA, and HHL) (Table 1 and Additional file 1: Table S1).
For O-type glycans, the glycan structure contained Galβ1-
3GalNAc (Jacalin and MPA) and GalNAcβ1-4GlcNAc
(WFA) (Table 1 and Additional file 1: Table S1). The most
intensive binding signal was detected in DSA and NPA
(Figure 3).
Identification and characterization of azide-labeled
sialoglycoproteins by LC-MS/MS
By using the strategy outlined in Figure 1, Steps 6 to 9,
75 unique formerly azido-sialic acid modified glycopep-
tides were identified in samples obtained from SW1990
cells treated with 1,3,4-O-Bu3ManNAz analog, represent-
ing 55 different glycoproteins (Table 2 and Additional
file 2: Table S2). The MS/MS annotation of all the
identified peptides is provided in Additional file 3:
Table S3. No glycoproteins were identified from cells
that were not treated with 1,3,4-O-Bu3ManNAc, indicat-
ing the specific enrichment and release of azido-sialic acidTable 1 Lectins showed specific binding signal to azide-modi
Lectin Full name Specificity*
DSA Datura stramonium (GlcNAcβ1-4
PHA-E Phaseolus vulgaris E Complex-typ
PSA Pisum sativum Fucα1-6GlcN
WFA Wisteria floribunda GalNAcβ1-4G
Jacalin Artocarpas integliforia Galβ1-3GalN
MPA Maclura pomifera Galβ1-3GalN
ECA Erythrina cristagalli Galβ1-4GlcN
UDA Urtica dioica GlcNAcβ1-4G
GNA Galanthus nivalis High-Man, M
HHL Hippeastrum Hybrid High-Man, M
NPA Narcissus pseudonarcissus High-Man, M
Calsepa Calystegia sepium Man, maltos
MNA-G Morus nigra G Man
VVA Vicia villosa α-Linked ter
*Lectin frontier Database; http://riodb.ibase.aist.go.jp/rcmg/glycodb/LectinSearch ancontaining sialoglycoproteins. Approximately 17% of the
proteins were identified by two or more unique glycopep-
tides, e.g., galectin-3-binding protein (GAL3BP) was identi-
fied by 5 glycopeptides, and lysosome-associated membrane
glycoprotein 1 (LAMP1) identified by 4 glycopeptides.
Analysis of metabolically labeled sialoglycoproteins
labeled with azido-sialoglycans
To gain insight into the biological activities of the glyco-
proteins that had been isolated and identified from the
1,3,4-O-Bu3ManNAz treated SW1990 cells, GO analysis
was performed [38]. The analysis of cellular component
shows that the majority of identified proteins (83%) are
extracellular proteins, including cell membrane proteins
and secreted proteins. The analysis of molecular function
shows that these glycoproteins play important roles in cell
signal transduction and cell-cell interaction including
catalytic activity (32.7%), receptor activity (29.1%), binding
(25.5%), enzyme regulator activity (5.5%), transporter ac-
tivity (5.5%), and ion channel activity (1.8%). The analysis
of biological process again reveals a broad range of activ-
ities for the identified proteins including cellular process
(15.0%), metabolic process (14.4%), cell communication
(12.4%), immune system process (11.8%), cell adhesion
(11.1%), response to stimulus (8.5%), and developmental
process (6.5%). Investigation of the identified sialoglyco-
proteins using previous reported glycoproteins showed
that among the 55 identified sialoglycoproteins labeled by
sialic acid analog, 42 proteins have documented correl-
ation with cancer (Additional file 2: Table S2), including
the 4F2 cell-surface antigen, CD 109 antigen, integrin β1,
and carboxypeptidase D [39-42]. In addition, fifteen of the
proteins have been specifically linked to pancreatic cancerfied glycoproteins
p value
)n, Galβ1-4GlcNAc <0.01
e N-glycans with outer Gal and bisecting GlcNAc <0.05
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d references [36,37].
Table 2 Identification of azido-sialic acid modified N-linked sialoglycoproteins
Protein group accessions Protein name Gene symbol
167466198 Intercellular adhesion molecule 1 ICAM1
296010912 Tissue factor CD142
7669492 Glyceraldehyde-3-phosphate dehydrogenase GAPD
4503143 Cathepsin D CTSD
4505467 5′-nucleotidase isoform 1 NT5E
4507483 Thrombomodulin THBD
9845238 UDP-GlcNAc:βGal β-1,3-N-acetylglucosaminyltransferase 2 B3GNT2
223468595 Integrin α-V Itgav
20150648 Chain A,Human Dipeptidyl Peptidase I (Cathepsin C) CTSC
19743823 Integrin β-1 Itgb1
29550838 Golgi membrane protein 1 GOLM1
53829379 Urokinase plasminogen activator surface receptor PLAUR
94962177 Activated leukocyte cell adhesion molecule variant 1 Alcam
38327634 ATP-dependent RNA helicase DDX18 DDX18
51247095 Chain T, Tissue Factor-Factor Viia Complex
116534898 Desmoglein-2 DSG2
4505061 Cation-dependent mannose-6-phosphate receptor M6PR
22202611 Carboxypeptidase D cpd
85544358 Chain C, A Minimal Gas6-Axl Complex
227430301 CD109 antigen CD109
4507509 Metalloproteinase inhibitor 1 TIMP1
189458817 Transferrin receptor protein 1 TFRC
4959370 Radical fringe RFNG
91199546 CD63 antigen CD63
5031863 Galectin-3-binding protein LGALS3BP
6014587 Mesothelin/megakaryocyte potentiating factor MSLN
10863927 Peptidyl-prolyl cis-trans isomerase A PPIAL3
149363636 Plexin-B2 plxnb2
157266292 Intestinal-type alkaline phosphatase ALPI
294660768 MHC class I polypeptide-related sequence A (MICA*00801) MICA
27754771 Protocadherin-1 PCDH1
222831610 Choline transporter-like protein 2 SLC44A2
47419930 Chondroitin sulfate proteoglycan 4 cspg4
32967311 Ephrin type-A receptor 2 EPHA2
4758950 Peptidyl-prolyl cis-trans isomerase B ppiB
112380628 Lysosome-associated membrane glycoprotein 1 lamp1
4504957 Lysosome-associated membrane glycoprotein 2 lamp2
38569398 Integrin α-10 ITGA10
4506113 Major prion protein PRNP
21536337 Myelin protein zero-like protein 2 MPZL2
187828910 CD59 glycoprotein CD59
10092665 Sushi domain-containing protein 2 Susd2
68163411 CD166 antigen Alcam
190194386 Transmembrane 9 superfamily member 3 TM9SF3
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Table 2 Identification of azido-sialic acid modified N-linked sialoglycoproteins (Continued)
180225 Carcinoembryonic antigen CEACAM5
270483821 Tetraspanin-3 TSPAN3
7657373 Tetraspanin-13 TSPAN13
61744483 4F2 cell-surface antigen heavy chain SLC3A2
24308201 Adipocyte plasma membrane-associated protein C20orf3
5542165 Chain A, Human Platelet Profilin Complexed With An L-Pro10- Iodotyrosine Peptide
5453832 Hypoxia up-regulated protein 1 hyou1
310125063 HLA class I histocompatibility antigen, A-43 α chain-li
148728160 Receptor-type tyrosine-protein phosphatase eta PTPRJ
166235138 Seizure 6-like protein 2 isoform 3 sez6l2
166235140 Seizure 6-like protein 2 isoform 4 sez6l2
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glyceraldehyde-3-phosphate dehydrogenase, intercellular
adhesion molecule 1, mesothelin, and tissue factor [43-47].
Implications of cancer-specific sialoglycoproteins
identified from metabolically glycoengineered cells
To test whether the glycoproteins identified from our
metabolic oligosaccharide engineering approach have
potential clinical significance (e.g., as biomarkers),
immunohistological analysis was performed on cancerous
and non-cancerous pancreatic tissue. Lysosome-associated
membrane glycoprotein 1(LAMP1) and hypoxia up-
regulated protein 1 (ORP 150) were chosen for analysis
in this regard because they previously have not been asso-
ciated with pancreatic cancer. LAMP1 is a glycoprotein
usually expressed in endosomes and lysosomal substructures
of cells with less expression on the plasma membrane
[48,49]. Elevated expression of LAMP1 at the cell surface
has been reported in metastatic tumor cells although no
link with pancreatic cancer has been reported [50]. Simi-
larly, no connection with pancreatic cancer yet has been
reported for ORP 150, a protein that plays a role in pro-
tein folding and secretion in the ER and hypoxia-induced
cellular perturbation and is up-regulated in certain tu-
mors, especially in breast cancer [51-55].
The protein expression of LAMP1 and ORP150 was
investigated by immunohistochemistry in eight pairs of
pancreatic cancer and matched non-tumorous pancreas
tissue sections. All pathological materials and the IHC
results were reviewed and scored by an American Path-
ology Boards certified pathologist. Figure 4A showed
that LAMP1 was over-expressed in tumor cells but not
in the paired nontumorous pancreas ductal cells. Seven
of eight pancreatic cancer cases were stained strongly
(score ≥ +2) while no staining was detected in matched
nontumorous pancreas tissues. A similar phenomenon
was observed for ORP150. The expression of ORP150 in
cancer cells was significantly increased as compared to
adjacent tumor-matched normal pancreas ductal cells(Figure 4B). Numbers of no/weak staining and moderate/
strong staining was compared between tumor cells
and matched nontumorous pancreas ductal cells. Both
LAMP1 and ORP150 showed over-expressions in pan-
creatic tumor cells (P-value = 0.0014).
Discussion
Glycosylation is a complex co-/post-translational modifi-
cation of proteins that mediates a variety of cell surface
recognition and binding events, participates in many
facets of the vertebrate immune response and contribute
to the progression of many diseases including the focus
of this study, which is cancer [56]. Glycans, however,
have remained relatively poorly understood because of
challenges in identifying glycoproteins, determining the
occupancy status and precise oligosaccharide structures
located at specific glycosylation sites due largely to the
complexity of the glycosylation process [56]. In this
study, we used metabolic oligosaccharide engineering
methods to identify the sialoglycoproteins modified by
azido-sugar in metabolically engineered pancreatic can-
cer cells when the cells were over-supplied with sialic
acid substrate analog.
Pancreatic cancer is the fourth leading cause of death by
cancer in Europe and in the US [57]. Among the common
malignancies, pancreatic cancer has the highest mortalities
with a 5-year survival rate of less than 5% [58,59]. Poor
prognosis of pancreatic cancer is due to the aggressive na-
ture of this disease, rapid metastasis, and late diagnosis of
the malignancy [60]. Thus, identification of biomarkers as
targets to diagnose and treat pancreatic cancer is urgently
needed, which provides the impetus for our efforts to dis-
cover pancreatic cancer-associated sialoglycoproteins in
the current report.
Because the heterogeneity of protein glycosylation is
evidenced by a number of potential glycosylation sites on
individual glycoprotein, different glycosylation sites may
be modified by different carbohydrates, of which abun-
dance may also differ from the protein expression level
(i) Nontumorous tissue 
(H&E)
(ii) Nontumorous tissue 
(IHC)
(iii) Tumor (H&E) (iv) Tumor (IHC)
(A) LAMP1 
(i) Nontumorous tissue 
(H&E)
(ii) Nontumorous vs. 
tumor (IHC)
(iii) Nontumorous tissue 
(IHC) (40X) 
(iv) Tumor (IHC)(40X) 
(B) ORP150
Figure 4 Verification of protein expression in pancreatic cancer and matched nontumorous pancreas tissues using IHC. (A) Increased expression
of LAMP1 in pancreatic tumor: (i) H&E staining of nontumorous pancreas duct, (ii) low expression of LAMP in matched nontumorous pancreas
ductal cells, (iii) H&E staining of pancreatic tumors, and (iv) overexpression of LAMP in pancreatic tumor. (B) Increased expression of ORP150 in
pancreatic cancer tissue as compared to matched nontumorous pancreas duct: (i) H&E staining of pancreas tumor and adjacent nontumorous
pancreas duct, (ii) IHC of nontumorous pancreas duct versus pancreatic tumor, (iii) a high power view of adjacent nontumorous pancreas duct,
and (iv) A high power view of a pancreatic tumor. The blue arrows indicate the nontumorous pancreas ductal cells, and red arrows indicate
pancreatic tumor cells.
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engineering to isolate sialoglycoproteins and associated
proteins in the protein mixture [29], the major advantage
of the approach used in this study is the capture of azido
labeled sialoglycopeptides and enzymatic release of N-
linked sialoglycopeptides for mass spectrometry iden-
tification of sialoglycosylation sites. The procedure allows
the identification of not only the isolated proteins, but also
the specific N-glycosylation sites that may contribute to
more sensitive and specific identification of sialoglyco-
proteins [29]. Another advantage of our approach compared
to previous reports is the use of synthetic azido-derivatized
ManNAc analog 1,3,4-O-Bu3ManNAz, which is capable of
supporting higher metabolic flux through the sialic acid
biosynthetic pathway at low concentrations compared to
Ac4ManNAz [29,34].
Seventy-five unique formerly azido-sialic acid modified
glycopeptides were identified from 55 glycoproteins
using 1,3,4-O-Bu3ManNAz analog treatment (Table 2
and Additional file 2: Table S2). The number of proteins
we identified was relatively low compared to whole gly-
coproteome datasets, in which hundreds or even thou-
sands of glycoproteins are expected to be expressed in aparticular cell type. However we emphasize that we delib-
erately did not seek to maximize detection of all possible
sialoglycans in the present study but rather conducted our
experiments in a way that would be most conducive to
the identification of cancer-associated biomarkers. In par-
ticular, we first limited the labeling period to two days
even though evidence suggests that non-natural sialic
acids can accumulate in tissue over a 6-week period upon
repeated daily dosing [62]; we consider it to be unlikely
that a diagnostic test could be conducted in a clinically-
relevant manner over this extended period (instead we
used a 2-day period in which a single bolus of analog has
been shown to resist esterase degradation [63] and further,
maximize cellular labeling without the need for added
doses or replenishment). Second, the number of cells in-
volved in each experiment (<10e7) coupled with the sub-
femtomolar mass spec detection sensitivity limit implies
that only relatively abundant markers (e.g., glycoproteins
expressed in the hundreds to thousands of copies per cell)
will be detected by our methods; again, this feature is de-
sired to ensure that our methods will have clinical rele-
vance where sample size is likely to be limiting. Finally, as
described in our previous publication [9], we use stringent
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factors – by design – limit the number of glycoproteins
that are identified by our method and ensure that the gly-
coproteins we identify will be sufficiently abundant and
metabolically labeled with sufficient kinetics to be viable
cancer biomarkers.
Another matter of interest is the exact glycan struc-
tures that the non-natural azido-modified sialic acids
label in cancer cells. In our previous experiments using
1,3,4-O-Bu3ManNAc, which increased levels of natural
sialic acid by ~75% in treated cells [9], the levels of sialy-
lation were sufficiently higher in the treated cells to
allow characterization of the new glycoforms by using
mass spectrometry-based methods [64]. By comparison,
treatment of cells with non-natural analogs tends to re-
sult in the replacement of natural sialic acids with their
non-natural counterparts rather than an overall increase
in sialylation (for perspective on this issue, consult refer-
ences [65-68]. In general, even though several million
non-natural sialic acids can be incorporated on the sur-
face of metabolically oligosaccharide engineered cancer
cells [69], the number of these moieties constitute only a
small percentage of the hundreds of millions of sialic
acids typically found on each human cell [69]. Conse-
quently, rigorous detection of non-natural sialic acids by
unambiguous techniques such as mass spectrometry be-
cause of their low abundance remains extremely challen-
ging and alternative approaches such as lectin binding
assays have provided some insight.
Lectins have long been used for purification and detec-
tion of glycans in many studies [70]; many lectins have
overlapping affinity while some others have unique spe-
cificity, allowing for the efficient detection of differential
expression of glycan structure. In the current studies the
use of a previously-reported lectin array [35] showed sig-
nificant binding signal from fourteen lectins (p < 0.05),
indicating α-1-6 core fucoses (PSA), Galβ1-4GlcNAc
structures (DSA and PHAE), high mannose (NPA, GNA,
and HHL) among the N-type glycans, and Galβ1-
3GalNAc (Jacalin and MPA) and GalNAcβ1-4GlcNAc
(WFA) for O-type glycans (Figure 3 and Table 1). This
data provided rudimentary insight into the glycan struc-
tures compatible with azido-sialic acid incorporation but
the most interesting aspect of these experiments was
the lack of. lectin binding to native sialic acid despite
the presence of the appropriate lectins (e.g., SNA) on
the array and the plentiful display of sialic acids on
SW1990 cells demonstrated in our previous experi-
ments [9,64]. Possible explanations for this outcome
include that 1) azido-sialic acid was not well recog-
nized by, or had weak binding, to sialic acid specific
lectins, such as SNA or that 2) the proteins modified
by native sialic acid are not simultaneously modified
by azido-sialic acid.As a final part of this project, we return to the initial
motivation of this study, which was to use metabolic oligo-
saccharide engineering methodology to identify cancer-
associated biomarkers in pancreatic cancer. This task is
complicated by not having a high quality “normal” pancre-
atic line that readily grows in cell culture conditions for
comparison. Therefore, one way we attempted to address
this issue was to cross-reference the list of the 55 proteins
we identified against cancer (in general) and pancreatic
cancer (more specifically) and found that 42 proteins have
been reported to be associated with cancer in general
and 15 have been specifically linked to pancreatic cancer
(Additional file 2: Table S2). Although encouraging, the
significance of this type of analysis is open to interpret-
ation considering that many of the proteins are linked to
cancer by as few as one reference, and further, it is not un-
expected to detect cancer-related proteins by analyzing
cancer cells. Therefore, we tried an alternative approach
that we consider to be more stringent by analyzing clinical
samples for two proteins (LAMP1 and ORP150) not
previously associated with pancreatic cancer and found
preferential expression in tumors compared to normal tis-
sue in both cases (Figure 4). Although far from definitive
(for example, comprehensive analysis of all the identified
glycoproteins is beyond the scope of the current investiga-
tion), this early result strongly supports our metabolic
oligosaccharide engineering approach as a viable strategy
for the identification of new cancer biomarkers.
In conclusion, this paper describes a strategy to analyze
metabolically active sialoglycoproteins found in pancreatic
cancer cells and shows that robust labeling of several
proteins already associated with tumors occurs. Even more
significantly, the positive evaluation of two proteins not
previously associated with pancreatic cancer in clinical
samples suggests that this method may be a powerful
technique for biomarker discovery. In summary, the re-
sults showed that metabolic oligosaccharide engineering
had broader implications by the discovery of sialoglyco-
proteins in cancer cells that hold potential for the diagno-
sis of cancer or as cell surface therapeutic targets [71].
Materials and methods
Cell culture
The pancreatic cell line, SW1990, was purchased from the
American Type Culture Collection (ATCC; Manasses,
VA). Cells were grown in 1:1 DMEM medium supple-
mented with 10% (v/v) FBS and 1% (v/v) of a solution of
10,000 units penicillin and 10 mg streptomycin/mL, at
37°C and 5% CO2.
Metabolic labeling of cells and cell surface azide
visualization via fluorescence microscopy
Pancreatic cells were seeded on 6-well TC plates and syn-
thetic 1,3,4-O-Bu3ManNAz analog [34] from a 50 mM
Tian et al. Clinical Proteomics  (2015) 12:11 Page 10 of 13stock solution was added to each well prior seeding the
cells to provide a final concentration of 50 μM. Cells were
incubated for two days with or without the analog. Prior
to visualization, the cells were washed with PBS and fixed
with 3.7% formaldehyde for 20 min at room temperature.
Labeling was done by adding 200 μL of a freshly prepared
Click Reaction Mixture to each well followed by incuba-
tion in the dark for 45 min as described previously [34].
The cells were then washed 3–5 times with PBS contain-
ing 5% BSA. Images were taken using a Zeiss Observer
microscope with a 40X objective lens (Zeiss, Inc., Melville,
NY). Fluorescence pictures of Alexa488 (surface sialogly-
coconjugates), and DAPI (nucleus) labeled cells were re-
corded and overlay images were generated with the Zeiss
Imaging System.
Biotinylation of azido-sialic acid containing glycoproteins
To selectively biotinylate azido-sialic acid modified glyco-
proteins, the modified Staudinger ligation reaction reported
by Saxon and coworkers using Biotin-PEG3-Phosphine was
performed on proteins extracted from cell lysates [15].
The protein concentration was adjusted to 2.5 mg/mL in
PBS (pH 7.2), Biotin-PEG3-Phosphine was added to a
final concentration of 200 μM. The sample was incubated
overnight at room temperature. The biotinylation effi-
ciency and specificity was examined by Western blot using
HRP-streptavidin at 1:5000. The non-reacted Biotin-
PEG3-Phosphine was removed through protein precipita-
tion. The proteins were mixed with an 8-fold volume of
pre-chilled (−20°C) acetone by vortexing and then incu-
bated at −20°C for 60 min. The samples were centrifuged
at 13,000 × g for 10 min. The supernatant was removed
and disposed without disturbing the protein pellet. This
washing and precipitation process was repeated and re-
sidual acetone was allowed to evaporate from the un-
capped tube at room temperature for 30 min.
Affinity purification of biotinylated proteins
A 50% slurry of monomeric avidin agarose (1.4 mL)
resin was sequentially washed with 3 mL PBS, 3 mL of
2 mM D-biotin in PBS, 3 mL of 0.1 M glycine (pH 2.8),
and 3 mL PBS. Protein (500 μg per sample, isolated from
treated or untreated cells as described above) was added to
the pre-conditioned monomeric avidin agarose resin and
incubated at room temperature for 1 h, followed by five
washes with 6 mL PBS. The biotinylated azido-modified
glycoproteins were eluted with 0.7 mL of 2 mM D-biotin
in PBS for 10 min followed by a second elution step of
0.7 mL of 0.1 M glycine (pH 2.8) for 10 min.
Characterized sialic acid glycans using lectin microarrays
A lectin microarray comprised of 38 lectins as described
in our previous study was used to profile the glycan
structures of the proteins biotinylated via Staudingerligation [35]. Each lectin was prepared in three concen-
trations (1, 0.5, and 0.25 mg/mL) on the chip. The slides
were blocked with 50 mM ethanolamine in 40 mM so-
dium borate for 1 h followed by three subsequent washes
with PBS-0.1% Tween. The biotinylated proteins (100 μL)
were applied to each lectin microarray. Inhibitory sugar
solutions (e.g. 100 μL of 50 mM lactose, 50 mM galactose,
50 mM mannose, or 50 mM acetic acid) were mixed with
samples, and then were applied to the control wells. After
an overnight incubation at room temperature, each well
was washed with 100 μL of PBS-0.1% Tween 20 with
5 min shaking. Rabbit IgG (20 μg) was added to each
array followed by a 30 min incubation to mask any re-
sidual lectin sites. The slides were washed three times with
PBS-0.1% Tween 20. Afterwards, 100 μL of streptavidin
conjugated to Dylight 549 (diluted 500-fold in PBS-
0.1% Tween) was added to each well and incubated
for 30 min in the dark before the array was washed,
dried, and scanned with a GenePix 4100B scanner
(Sunnyvale, CA).
Identification of formerly azide-sialic acid modified
glycopeptides
After biotinylation and removal of the non-reacted Biotin-
PEG3-Phosphine using protein precipitation, 1 mg of pro-
tein was denatured and reduced in 8 M urea, 10 mM
TCEP, and 1% SDS in 200 mM Tris buffer at 37°C for 2 h
[72]. Iodoacetamide (10 mM final concentration) was
added to the sample and incubated for 30 min at RT in
the dark. The solution was diluted 8-fold with 100 mM
KH2PO4 (pH 8.0). The proteins were digested by trypsin
(Promega, 1:50, w/w) at 37°C overnight with shaking.
After digestion, the samples were centrifuged at 16,110 ×
g for 5 min to remove particulate matter. The peptides
were cleaned by using a Sep-Pak C18 Vac cartridge
(Waters) and resuspended in PBS. Six hundred microli-
ters of 50% slurry of streptavidin agarose resin was washed
with 1 mL PBS (pH 7.2) three times. Protease inhibitor
(Pierce) was added to the peptides at a 1:1000 dilution
prior to mixing peptides with pre-washed streptavidin
agarose. The peptides were allowed to bind to streptavidin
agarose at room temperature for 15 min. The unbound
peptides were removed by centrifugation. The streptavidin
agarose was washed with 1 mL PBS 6 times, then resus-
pended in 250 μL G7 buffer (New England Biolabs) and
peptides containing N-linked glycosylation sites with
metabolic labeled sialoglyans were released by PNGase F
(New England Biolabs) [73-75]. The peptides were an-
alyzed using a LTQ-Orbitrap velos (ThermoFisher,
Waltham, MA) coupled with a 15 cm × 75 μm C18
column (5 μm particles with 100 angstrom pore size). The
spectra were analyzed as described in our previous report
[76]. Briefly, a nanoAquity UPLC at 300 nL/min with a
90 min linear acetonitrile gradient (from 5-32% B over
Tian et al. Clinical Proteomics  (2015) 12:11 Page 11 of 1390 min; A = 0.1% formic acid in water, B = 0.1% formic
acid in acetonitrile) was used. A top 10 data dependent
MS/MS with exclusion for 20 s was set.
MS/MS spectra were searched with MASCOT (version
2.2.0) using Proteome Discoverer (version 1.0) (Thermo
Fisher) against human subdatabase of NCBI Reference
Sequence (RefSeq) (version 40, released at April 16,
2010) containing 29,704 sequences. For this database
search, the precursor mass tolerance and fragment mass
tolerance were set at 15 ppm and 0.05 Da respectively.
Trypsin was specified as the protease. The fixed modifi-
cation was set as carbamidomethylation (C), and other
database-searching parameters were set as flexible modi-
fication as follows: deamidation (NQ) and oxidation (M).
Semi-tryptic end and one missed cleavage site was allowed.
The False Discovery Rate was set at 0.01 to eliminate low-
probability protein identifications.
Identified proteins were classified according to their
main biological processes, their molecular functions and
their cellular component using “Blast2Go” software
(www.blast2go.com) [38].Immunohistochemistry (IHC)
Formalin-fixed and paraffin-embedded tumor tissue was
obtained from the Department of Pathology at Johns
Hopkins Hospital, and was cut into 4-micron sections.
Slides were de-paraffined and rehydrated before IHC
study. Dako LSAB+ System-AP kit (Carpinteria, CA)
used for IHC study according to the manufacturer’s in-
structions. Antigen-retrieval using 10 mM sodium citrate
(pH 6.0) at 100°C for 20 min was performed prior to apply
mouse monoclonal anti- human LAMP1 antibody at
1:150 dilution. The mouse monoclonal anti- human
ORP150 antibody was applied to slides at 1:200 dilution
without antigen retrieval. The primary antibodies were in-
cubated overnight at 4°C. All pathological materials and
IHC results were reviewed and evaluated by an American
Pathology Boards certified pathologist, Dr. Qing Kay Li.
The cytoplasmic immuno-staining pattern and immuno-
reactive intensity were scored semi-quantitatively using a
4 tier system: no staining (0), weak (1+, <10% positivity),
moderate (2+, 10-50% positivity), and strong (3+, >50%
positivity). The IHC staining pattern was correlated with
tumors’ pathological stages and the differentiations. Pa-
tients’ clinical information was also correlated. Fisher’s
exact test was used to determine the statistical significance
of IHC staining in pancreas tumor and paired normal pan-
creas tissues.Additional files
Additional file 1: Table S1. Information of 38 lectins used in lectin
microarray.Additional file 2: Table S2. Identification of N-glycosite-containing
sialoglycopeptides using LC-MS/MS.
Additional file 3: Table S3. MS/MS annotation for the identified
sialoglycopeptides.
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